COMPASS Pathways revealed positive topline results from the mental healthcare firm’s Phase IIB clinical trial on the use of COMP360 psilocybin to address treatment-resistant depression (TRD). 

A new study helps quantify the improved protection against Covid-19 achieved with a third booster dose of the vaccine from Pfizer Inc. and BioNTech SE in cancer patients who are undergoing chemotherapy.

Sage Therapeutics and Biogen announced positive and consistent results from their ongoing clinical trials on the efficacy and safety of zuranolone in treating major depressive disorder (MDD) and postpartum depression (PPD).

Sage Therapeutics ended two late-stage studies of the depression drug zuranolone after discussions with the U.S. Food and Drug Administration led the company to believe they were unnecessary for potential regulatory approval.

Sage Therapeutics’ experimental depression drug showed significant improvement in symptoms compared to placebo in a late-stage study.

More young adults in the United States reported feeling anxious or depressed during the past six months of the COVID-19 pandemic, and fewer people reported getting the help they needed, according to a U.S. government study released on March 26.

Novartis is acquiring Cambridge, Massachusetts-based neuroscience company Cadent Therapeutics for a $210 million upfront payment and potentially $560 million in milestone payments.

Shares of Axsome Therapeutics were up after the company announced positive long-term results from a Phase III major depressive disorder (MDD) study that sets up potential regulatory approval for AXS-05.

More than half of Covid-19 patients discharged from hospitals still experienced symptoms of breathlessness, fatigue, anxiety and depression for two to three months after their initial infection, according to the findings of a small UK study.

Cambridge, Massachusetts-based Praxis Precision Medicines raised about $110 million in a Series C financing, led by Eventide Asset Management,